Your browser doesn't support javascript.
loading
P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
Sands, Bruce; Pondel, Marc; Silver, Michael; Petersen, AnnKatrin; Wolf, Douglas; Panaccione, Remo; Loftus, Edward; Colombel, Jean-Frederic; Sturm, Andreas; D'Haens, Geert.
Afiliação
  • Sands B; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
  • Pondel M; Bristol Myers Squibb, Princeton, New Jersey, United States.
  • Silver M; Bristol Myers Squibb, Princeton, New Jersey, United States.
  • Petersen A; Bristol Myers Squibb, Princeton, New Jersey, United States.
  • Wolf D; Center for Crohn's Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, Georgia, United States.
  • Panaccione R; Inflammatory Bowel Disease Clinic, Gastrointestinal Research, Cumming School of Medicine, University of Calgary, Calgary, Canada.
  • Loftus E; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
  • Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States.
  • Sturm A; Division of Gastroenterology, DRK Kliniken Berlin Westend, Berlin, Germany.
  • D'Haens G; Inflammatory Bowel Disease Center, Amsterdam University Medical Center, Amsterdam, Netherlands.
Am J Gastroenterol ; 116(Suppl 1): S8, 2021 Dec 01.
Article em En | MEDLINE | ID: mdl-37461950
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2021 Tipo de documento: Article